Product Description
Aciclovir is a synthetic compound with a similar molecular structure to purine nucleoside. It has been shown to stop the growth of herpes simplex virus (HSV), Varicella zoster virus (VZV) (the cause of chickenpox and shingles), Epstein-Barr virus (EBV, the cause of infectious mononucleosis), and to a lesser extent cytomegalovirus (CMV).
Mechanisms of Action: DNA Polymerase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Poland, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Herpes Labialis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-510338-10-00 |
OP-LIPC02 | P3 |
Recruiting |
Herpes Labialis |
2025-10-25 |
2025-05-02 |
Treatments |
|
NCT05098938 |
NCT05098938 | P3 |
Completed |
Herpes Labialis |
2023-07-19 |
19% |
2025-09-03 |
Patient Enrollment|Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/16/2025 |
News Article |
Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Patients with Refractory Herpes Simplex Virus in Phase 3 Pivotal Trial |
|
09/24/2025 |
News Article |
Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus |
|
09/16/2025 |
News Article |
Aicuris Announces Upcoming Oral and Poster Presentations at ID Week 2025 |
|
07/24/2025 |
News Article |
Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients |